{"title":"肺癌手术后静脉血栓栓塞风险:系统回顾和荟萃分析。","authors":"Jing Chen, Yuanzheng Mao, Zhiyu Peng","doi":"10.1007/s11239-025-03164-5","DOIUrl":null,"url":null,"abstract":"<p><p>Venous thromboembolism (VTE) remains a major contributor to postoperative morbidity and mortality in patients undergoing lung cancer surgery. This study aims to identify perioperative risk factors associated with VTE development following such procedures. We performed an exhaustive search of PUBMED and EMBASE from inception to November 1, 2023, using terms related to VTE following lung cancer surgery. A random-effects meta-analysis was performed to calculate the pooled incidence and odds ratios (ORs) for risk factors. Of 3,576 screened studies, 13 met eligibility criteria for qualitative synthesis, and 11 studies (53,382 patients) were included in the meta-analysis. The pooled incidence of postoperative VTE was 1.82% (971 cases). Significant risk factors included advanced age (standardized mean difference [SMD] 0.43, 95% CI 0.22-0.63; I<sup>2</sup> = 59.9%), prolonged surgical duration (SMD 0.58, 95% CI 0.24-0.92; I<sup>2</sup> = 81.2%), open thoracotomy (OR 1.77, 95% CI 1.50-2.09; I<sup>2</sup> = 19.9%), TNM stage > 1 (OR = 1.81, 95% CI 1.53-2.13; I<sup>2</sup> = 39.8%), adenocarcinoma histology (OR = 1.29, 95% CI 1.08-1.53; I<sup>2</sup> = 1.2%), and major lung resection (OR = 1.51, 95% CI 1.24-1.83; I2 = 0.0%). This study highlights key modifiable and non-modifiable risk factors for postoperative VTE in lung cancer surgery patients. These findings support individualized risk stratification and targeted thromboprophylaxis strategies to improve clinical outcomes.</p>","PeriodicalId":17546,"journal":{"name":"Journal of Thrombosis and Thrombolysis","volume":" ","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2025-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Postoperative venous thromboembolism risk following lung cancer surgery: a systematic review and meta-analysis.\",\"authors\":\"Jing Chen, Yuanzheng Mao, Zhiyu Peng\",\"doi\":\"10.1007/s11239-025-03164-5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Venous thromboembolism (VTE) remains a major contributor to postoperative morbidity and mortality in patients undergoing lung cancer surgery. This study aims to identify perioperative risk factors associated with VTE development following such procedures. We performed an exhaustive search of PUBMED and EMBASE from inception to November 1, 2023, using terms related to VTE following lung cancer surgery. A random-effects meta-analysis was performed to calculate the pooled incidence and odds ratios (ORs) for risk factors. Of 3,576 screened studies, 13 met eligibility criteria for qualitative synthesis, and 11 studies (53,382 patients) were included in the meta-analysis. The pooled incidence of postoperative VTE was 1.82% (971 cases). Significant risk factors included advanced age (standardized mean difference [SMD] 0.43, 95% CI 0.22-0.63; I<sup>2</sup> = 59.9%), prolonged surgical duration (SMD 0.58, 95% CI 0.24-0.92; I<sup>2</sup> = 81.2%), open thoracotomy (OR 1.77, 95% CI 1.50-2.09; I<sup>2</sup> = 19.9%), TNM stage > 1 (OR = 1.81, 95% CI 1.53-2.13; I<sup>2</sup> = 39.8%), adenocarcinoma histology (OR = 1.29, 95% CI 1.08-1.53; I<sup>2</sup> = 1.2%), and major lung resection (OR = 1.51, 95% CI 1.24-1.83; I2 = 0.0%). This study highlights key modifiable and non-modifiable risk factors for postoperative VTE in lung cancer surgery patients. These findings support individualized risk stratification and targeted thromboprophylaxis strategies to improve clinical outcomes.</p>\",\"PeriodicalId\":17546,\"journal\":{\"name\":\"Journal of Thrombosis and Thrombolysis\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2025-08-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Thrombosis and Thrombolysis\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s11239-025-03164-5\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Thrombosis and Thrombolysis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11239-025-03164-5","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
摘要
静脉血栓栓塞(VTE)仍然是肺癌手术患者术后发病率和死亡率的主要原因。本研究旨在确定与此类手术后静脉血栓栓塞发展相关的围手术期危险因素。我们使用与肺癌手术后静脉血栓栓塞相关的术语,对PUBMED和EMBASE从成立到2023年11月1日进行了详尽的搜索。进行随机效应荟萃分析以计算危险因素的合并发生率和优势比(ORs)。在3,576项筛选的研究中,13项符合定性综合的资格标准,11项研究(53,382例患者)被纳入meta分析。术后静脉血栓栓塞合并发生率为1.82%(971例)。显著危险因素包括高龄(标准化平均差[SMD] 0.43, 95% CI 0.22-0.63;I2 = 59.9%),手术时间延长(SMD 0.58, 95% CI 0.24-0.92;I2 = 81.2%)、开胸手术(OR 1.77, 95% CI 1.50-2.09;I2 = 19.9%), TNM阶段> 1 (OR = 1.81, 95% CI 1.53 - -2.13;I2 = 39.8%),腺癌组织学(OR = 1.29, 95% CI 1.08-1.53;I2 = 1.2%),大肺切除术(OR = 1.51, 95% CI 1.24-1.83;i2 = 0.0%)。本研究强调了肺癌手术患者术后静脉血栓栓塞的主要可改变和不可改变的危险因素。这些发现支持个体化风险分层和有针对性的血栓预防策略,以改善临床结果。
Postoperative venous thromboembolism risk following lung cancer surgery: a systematic review and meta-analysis.
Venous thromboembolism (VTE) remains a major contributor to postoperative morbidity and mortality in patients undergoing lung cancer surgery. This study aims to identify perioperative risk factors associated with VTE development following such procedures. We performed an exhaustive search of PUBMED and EMBASE from inception to November 1, 2023, using terms related to VTE following lung cancer surgery. A random-effects meta-analysis was performed to calculate the pooled incidence and odds ratios (ORs) for risk factors. Of 3,576 screened studies, 13 met eligibility criteria for qualitative synthesis, and 11 studies (53,382 patients) were included in the meta-analysis. The pooled incidence of postoperative VTE was 1.82% (971 cases). Significant risk factors included advanced age (standardized mean difference [SMD] 0.43, 95% CI 0.22-0.63; I2 = 59.9%), prolonged surgical duration (SMD 0.58, 95% CI 0.24-0.92; I2 = 81.2%), open thoracotomy (OR 1.77, 95% CI 1.50-2.09; I2 = 19.9%), TNM stage > 1 (OR = 1.81, 95% CI 1.53-2.13; I2 = 39.8%), adenocarcinoma histology (OR = 1.29, 95% CI 1.08-1.53; I2 = 1.2%), and major lung resection (OR = 1.51, 95% CI 1.24-1.83; I2 = 0.0%). This study highlights key modifiable and non-modifiable risk factors for postoperative VTE in lung cancer surgery patients. These findings support individualized risk stratification and targeted thromboprophylaxis strategies to improve clinical outcomes.
期刊介绍:
The Journal of Thrombosis and Thrombolysis is a long-awaited resource for contemporary cardiologists, hematologists, vascular medicine specialists and clinician-scientists actively involved in treatment decisions and clinical investigation of thrombotic disorders involving the cardiovascular and cerebrovascular systems. The principal focus of the Journal centers on the pathobiology of thrombosis and vascular disorders and the use of anticoagulants, platelet antagonists, cell-based therapies and interventions in scientific investigation, clinical-translational research and patient care.
The Journal will publish original work which emphasizes the interface between fundamental scientific principles and clinical investigation, stimulating an interdisciplinary and scholarly dialogue in thrombosis and vascular science. Published works will also define platforms for translational research, drug development, clinical trials and patient-directed applications. The Journal of Thrombosis and Thrombolysis'' integrated format will expand the reader''s knowledge base and provide important insights for both the investigation and direct clinical application of the most rapidly growing fields in medicine-thrombosis and vascular science.